{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.06","upperLimit":"12.64","value":"1.55"},{"groupId":"OG001","lowerLimit":"-4.84","upperLimit":"11.54","value":"0.98"},{"groupId":"OG002","lowerLimit":"-5.81","upperLimit":"7.46","value":"0.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"Change in total body lean mass as measured by dual energy x-ray absorptiometry (DEXA)from baseline to 4 months.","dispersionType":"Full Range","groups":[{"id":"OG000","title":"GTx-024 1 mg"},{"id":"OG001","title":"GTx-024 3 mg"},{"description":"Placebo","id":"OG002","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The number of participants were those subjects in the modified intent-to-treat population (defined as subjects with at least one post baseline DEXA for LBM) who had baseline and 4 month DEXA results for LBM (observed cases).","reportingStatus":"POSTED","timeFrame":"Baseline to Four Months","title":"The Efficacy of GTx-024 on Total Body Lean Mass.","type":"PRIMARY","unitOfMeasure":"kg"}